Stock MODTX MODUS THERAPEUTICS HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
2.08 SEK +47.52% Intraday chart for Modus Therapeutics Holding AB +63.14% +19.88%
May. 14 Modus Therapeutics Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 21 Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Annual General Meeting in Modus Therapeutics Holding AB (publ)
AQ
Modus Therapeutics publishes interim report for the first quarter 2024
AQ
Modus Therapeutics Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Notice to Annual General Meeting in Modus Therapeutics Holding
AQ
Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2023
AQ
Modus Therapeutics publishes year-end report for 2023
AQ
Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
The Rights Issue is Registered and Trading in Paid Subscribed Shares Ceases
AQ
Modus Therapeutics presented data on sevuparin demonstrating its potential to treat anemia in chronic kidney disease at the annual American Society of Hematology (ASH)
AQ
Modus Therapeutics Holding AB Announces Final Outcome in Rights Issue
AQ
Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue
AQ
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan
MT
Modus Therapeutics Holding AB Conducts a Rights Issue of 40.3 MSEK and an Offset Issue of 20.3 MSEK
AQ
Modus Therapeutics publishes interim report for the third quarter 2023
AQ
Modus Therapeutics Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Modus Therapeutics to present at the 2023 American Society of Hematology Meeting and Exposition (ASH): New data on sevuparin and its potential to treat chronic kidney disease anemia and reduce kidney injury.
AQ
Modus Therapeutics presents final data from its Phase 1b LPS-provocation study with sevuparin at the annual ISICIP symposium in Barcelona
AQ
Modus Therapeutics publishes interim report for the second quarter 2023
AQ
Modus Therapeutics Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Modus Therapeutics presented new data on sevuparin demonstrating its potential to treat anemia related to chronic diseases at the annual European Hematology Association Congress
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MODTX Stock
  4. News Modus Therapeutics Holding AB